These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. TAFIa inhibitors in the treatment of thrombosis. Bunnage ME; Owen DR Curr Opin Drug Discov Devel; 2008 Jul; 11(4):480-6. PubMed ID: 18600565 [TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087 [TBL] [Abstract][Full Text] [Related]
30. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia? Dusse LM; Cooper AJ; Lwaleed BA Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758 [TBL] [Abstract][Full Text] [Related]
31. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles. Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642 [TBL] [Abstract][Full Text] [Related]
32. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Boffa MB; Koschinsky ML Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488 [TBL] [Abstract][Full Text] [Related]
33. Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis. Sasaki T; Yoshimoto N; Sugimoto K; Takada K; Murayama N; Yamazaki H; Yamamoto K; Ishii H Thromb Res; 2012 Oct; 130(4):e222-8. PubMed ID: 22795218 [TBL] [Abstract][Full Text] [Related]
34. Myocardial infarction and the balance between fibrin deposition and removal. Nesheim M Ital Heart J; 2001 Sep; 2(9):641-5. PubMed ID: 11666089 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Do YH; Gifford-Moore DS; Beight DW; Rathnachalam R; Klimkowski VJ; Warshawsky AM; Lu D Thromb Res; 2005; 116(3):265-71. PubMed ID: 15935836 [TBL] [Abstract][Full Text] [Related]
36. Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease. Yoshimoto N; Sasaki T; Sugimoto K; Ishii H; Yamamoto K J Med Chem; 2012 Sep; 55(17):7696-705. PubMed ID: 22891675 [TBL] [Abstract][Full Text] [Related]
37. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Muto Y; Suzuki K; Iida H; Sakakibara S; Kato E; Itoh F; Kakui N; Ishii H Crit Care Med; 2009 May; 37(5):1744-9. PubMed ID: 19325462 [TBL] [Abstract][Full Text] [Related]
38. Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group. Itoh T; Yoshimoto N; Hirano Y; Yamamoto K Bioorg Med Chem Lett; 2018 Jul; 28(13):2256-2260. PubMed ID: 29859906 [TBL] [Abstract][Full Text] [Related]
39. [Effect and mechanism of recombinant hirudin on fibrinolysis]. Li M; Zhang RJ; Cao GX; Wan WX; Zhang LF; Jin J Yao Xue Xue Bao; 2006 Sep; 41(9):814-8. PubMed ID: 17111825 [TBL] [Abstract][Full Text] [Related]
40. Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome. Gursoy T; Tekinalp G; Yurdakok M; Ozcebe O; Korkmaz A; Gurgey A Am J Hematol; 2008 Jan; 83(1):50-3. PubMed ID: 17654683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]